Abstract
The dividing line between essential physiological inflammatory processes and excessive pathological inflammation is often very thin - in some circumstances, indeed, it may be non-existent. Devising anti-inflammatory medications that effectively target only the pathological component therefore remains a central challenge for the pharmaceutical industry. At present, the general rule is that the more powerful the antiinflammatory effect of a drug, the greater the side-effects that accompany it. Steroids, for example, are potent antiinflammatory medications, but they have a diverse array of side effects that substantially limit their use. Since chemokines play a central role in regulating the immune system, and in particular, the trafficking of leukocytes, inhibiting their action may represent a powerful new therapeutic strategy for treating diseases with an inflammatory component. However, this potential will only be realized if it is possible to interfere with chemokine signaling networks, without inducing unacceptable side effects. Although very little, direct human toxicology has been carried out using chemokine inhibitors, there is now a sufficient body of indirect and circumstantial evidence (for example, from genetically modified mice and from animal model studies using chemokine inhibitors) to allow a tentative assessment of the biological impact of chemokine inhibition. The purpose of this review is to outline the available data and to speculate on the likely toxicological profile resulting from chemokine inhibition. The tentative conclusion is that anti-inflammatory therapy achieved through chemokine inhibition may have fewer side effects than originally expected, even when the actions of multiple chemokines are inhibited simultaneously.
Keywords: immune system, macrophages, corticosteroids, inflammatory agents, broad-spectrum chemokine inhibitors, ccr antagonist, immunosuppression
Mini-Reviews in Medicinal Chemistry
Title: The Toxicology of Chemokine Inhibition
Volume: 5 Issue: 9
Author(s): Robert W. Schroff, Caroline Touvay, Michael D. Culler, Jesse Z. Dong, John E. Taylor, Christophe Thurieau and Elaine McKilligin
Affiliation:
Keywords: immune system, macrophages, corticosteroids, inflammatory agents, broad-spectrum chemokine inhibitors, ccr antagonist, immunosuppression
Abstract: The dividing line between essential physiological inflammatory processes and excessive pathological inflammation is often very thin - in some circumstances, indeed, it may be non-existent. Devising anti-inflammatory medications that effectively target only the pathological component therefore remains a central challenge for the pharmaceutical industry. At present, the general rule is that the more powerful the antiinflammatory effect of a drug, the greater the side-effects that accompany it. Steroids, for example, are potent antiinflammatory medications, but they have a diverse array of side effects that substantially limit their use. Since chemokines play a central role in regulating the immune system, and in particular, the trafficking of leukocytes, inhibiting their action may represent a powerful new therapeutic strategy for treating diseases with an inflammatory component. However, this potential will only be realized if it is possible to interfere with chemokine signaling networks, without inducing unacceptable side effects. Although very little, direct human toxicology has been carried out using chemokine inhibitors, there is now a sufficient body of indirect and circumstantial evidence (for example, from genetically modified mice and from animal model studies using chemokine inhibitors) to allow a tentative assessment of the biological impact of chemokine inhibition. The purpose of this review is to outline the available data and to speculate on the likely toxicological profile resulting from chemokine inhibition. The tentative conclusion is that anti-inflammatory therapy achieved through chemokine inhibition may have fewer side effects than originally expected, even when the actions of multiple chemokines are inhibited simultaneously.
Export Options
About this article
Cite this article as:
Schroff W. Robert, Touvay Caroline, Culler D. Michael, Dong Z. Jesse, Taylor E. John, Thurieau Christophe and McKilligin Elaine, The Toxicology of Chemokine Inhibition, Mini-Reviews in Medicinal Chemistry 2005; 5 (9) . https://dx.doi.org/10.2174/1389557054867093
DOI https://dx.doi.org/10.2174/1389557054867093 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Binding Modes of 2-Phenylamino-6-oxopurines to Herpes Simplex Virus Thymidine Kinases
Letters in Drug Design & Discovery Five Decades of Cuprizone, an Updated Model to Replicate Demyelinating Diseases
Current Neuropharmacology Childhood Infectious Encephalitis: An Overview of Clinical Features, Investigations, Treatment, and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Association between <i>Toxoplasma gondii</i> Infection and Headache: A Systematic Review and Meta-Analysis
Infectious Disorders - Drug Targets Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Viral Product Trafficking to Mitochondria, Mechanisms and Roles in Pathogenesis
Infectious Disorders - Drug Targets Neurological Manifestations of COVID-19 and the Importance of Magnetic Resonance Imaging
CNS & Neurological Disorders - Drug Targets Research Progress of Glycyrrhizic Acid on Antiviral Activity
Mini-Reviews in Medicinal Chemistry Antiviral Strategies: The Present and Beyond
Current Molecular Pharmacology Immunobiology of Herpes Simplex Virus and Cytomegalovirus Infections of the Fetus and Newborn
Current Immunology Reviews (Discontinued) The Development of High-throughput Identification and Heterologous Expression of Valuable Peptides/Proteins
Current Proteomics The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update
Current Medicinal Chemistry The Changing Face of Cytokines in the Brain: Perspectives From EAE
Current Pharmaceutical Design Applied Proteomics in Companion Animal Medicine
Current Proteomics Ebola Virus Altered Innate and Adaptive Immune Response Signalling Pathways: Implications for Novel Therapeutic Approaches
Infectious Disorders - Drug Targets Toll-Like Receptors: Sensor Molecules for Detecting Damage to the Nervous System
Current Protein & Peptide Science Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Current Alzheimer Research Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Internal Ribosome Entry Site Elements in Eukaryotic Genomes
Current Genomics Alphaviruses and their Derived Vectors as Anti-Tumor Agents
Current Cancer Drug Targets